GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Imagin Medical Inc (OTCPK:IMEXF) » Definitions » EV-to-EBITDA

IMEXF (Imagin Medical) EV-to-EBITDA : -23.89 (As of Apr. 25, 2025)


View and export this data going back to . Start your Free Trial

What is Imagin Medical EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Imagin Medical's enterprise value is $9.53 Mil. Imagin Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.40 Mil. Therefore, Imagin Medical's EV-to-EBITDA for today is -23.89.

The historical rank and industry rank for Imagin Medical's EV-to-EBITDA or its related term are showing as below:

IMEXF's EV-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 15.315
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-04-25), Imagin Medical's stock price is $0.0001. Imagin Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.042. Therefore, Imagin Medical's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Imagin Medical EV-to-EBITDA Historical Data

The historical data trend for Imagin Medical's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imagin Medical EV-to-EBITDA Chart

Imagin Medical Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.39 -1.06 -1.02 -1.39 -6.79

Imagin Medical Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.58 -1.77 -6.79 -14.71 -21.93

Competitive Comparison of Imagin Medical's EV-to-EBITDA

For the Medical Devices subindustry, Imagin Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imagin Medical's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Imagin Medical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Imagin Medical's EV-to-EBITDA falls into.


;
;

Imagin Medical EV-to-EBITDA Calculation

Imagin Medical's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=9.531/-0.399
=-23.89

Imagin Medical's current Enterprise Value is $9.53 Mil.
Imagin Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Imagin Medical  (OTCPK:IMEXF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Imagin Medical's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/-0.042
=At Loss

Imagin Medical's share price for today is $0.0001.
Imagin Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.042.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Imagin Medical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Imagin Medical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Imagin Medical Business Description

Traded in Other Exchanges
N/A
Address
890 West Pender Street, Suite 600, Vancouver, BC, CAN, V6C 1J9
Imagin Medical Inc is a surgical imaging company focused on developing technology to visualize cancer during minimally invasive procedures. Its initial focus is bladder cancer. Imagin's first product, the i/Blue Imaging System, is based on optics and light sensors and employs patented ultrasensitive imaging technology. The company believes the system, currently in the manufacturing stage, will significantly improve surgeon's ability to visualize and remove cancer cells. Run by a Boston-based management team, the company will work to enhance its market potential in the future by expanding its technology to multiple endoscopic procedures, such as laparoscopic and thoracic procedures, accommodating multiple contrast agents and illumination sources.